MIP Diagnostics

company

About

A synthetic antibody company based in East Midlands, UK.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
£1.50M
Industries
Biotechnology,Life Science,Medical
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

MIP Diagnostics Ltd was founded in 2015 as a spin out from the University of Leicester by several leading experts in the field, including Prof. Sergey Piletsky, in order to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called "plastic antibodies". Their proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. Whilst MIPs are exceptionally robust polymers [plastics], nanoMIPS are sufficiently small to be essentially soluble. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
£6.90M
MIP Diagnostics has raised a total of £6.90M in funding over 2 rounds. Their latest funding was raised on Jul 14, 2020 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 14, 2020 Series Unknown £5.10M 1 Detail
May 8, 2018 Series A £1.50M 1 Mercia Fund Managers Detail
Jun 30, 2017 Seed £300K 1 Mercia Fund Managers Detail
Jun 5, 2015 Seed 1 Mercia Fund Managers Detail

Investors

Number of Lead Investors
Number of Investors
3
1
MIP Diagnostics is funded by 1 investors. Mercia Fund Managers are the most recent investors.
Investor Name Lead Investor Funding Round
Mercia Fund Managers Series Unknown